Epirus Gets $36M in Financing; Agrees to Merge with Zalicus
April 17, 2014
Epirus Biopharmaceuticals has raised $36 million in Series B financing. The company has also agreed to merge with pain drug maker Zalicus (NASDAQ: ZLCS) in an all-stock transaction. Post-merger, the combined company will operate under the Epirus brand and trade on the NASDAQ, focusing on building a global biosimilar enterprise to improve patient access to important medicines.